Abstracts tagged "patient-reported outcome measures"

Abstract Number: 2654 • 2015 ACR/ARHP Annual Meeting
The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry
Dimitrios A. Pappas^1,2, Robert J. Holt³, Ying Shan⁴, Jeffrey D. Kent⁵, John T. Nguyen⁴, Joel M. Kremer⁶ and Jeffrey D. Greenberg^2,7, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³University of Illinois - Chicago, Chicago, IL, ⁴Corrona, LLC., Southborough, MA, ⁵Horizon Pharma USA, Inc., Deerfield, IL, ⁶Albany Medical College and The Center for Rheumatology, Albany, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: The ACR/EULAR Boolean definition of remission is expected to be used as an outcome measure in randomized clinical trials for rheumatoid arthritis (RA). Boolean…
Abstract Number: 2674 • 2015 ACR/ARHP Annual Meeting
Patient Global Assessment in Evaluating Boolean-Based Remission in Rheumatoid Arthritis-Is It Really Required Instead of Physician Global Assessment? a Comparative Study with Ultrasound
Gulsen Ozen¹, Ali Ugur Unal¹, Atakan Topcu², Pamir Atagunduz¹, Haner Direskeneli¹ and Nevsun Inanc¹, ¹Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ²Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Patient global assessment (PtGA) is included in all the current remission definitions for RA despite the fact that PtGA is not exclusively related to…
Abstract Number: 2682 • 2015 ACR/ARHP Annual Meeting
A Brief Patient-Reported Measure of Physical Function Is Sensitive to Changes in a Composite Disease Activity Measure in a Diverse Rheumatoid Arthritis Clinic Setting
Elizabeth R. Wahl^1,2, Andrew Gross², Vladimir Chernitskiy², Laura Trupin², Jinoos Yazdany³ and Patricia P. Katz², ¹Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) patients' physical function is a strong predictor of clinical outcomes. A brief patient-reported measure of physical function, the PROMIS PF-10a (PF-10a),…
Abstract Number: 2687 • 2015 ACR/ARHP Annual Meeting
Clinical Significance of Patient-Reported Pain and Stiffness at Each Joint Level in the Evaluation of Patients with Rheumatoid Arthritis
Ayako Hirata, Takehisa Ogura, Norihide Hayashi, Sayaka Takenaka, Hideki Ito, Kennosuke Mizushina, Yuki Fujisawa, Munetsugu Imamura, Naoko Yamashita and Hideto Kameda, Department of Rheumatology, Toho University Ohashi Medical Center, Tokyo, Japan
Background/Purpose: Patient-reported outcome has been considered as an important aspect in the evaluation of patients with rheumatoid arthritis (RA). Recently, ultrasonography (US) has been used…
Abstract Number: 998 • 2015 ACR/ARHP Annual Meeting
A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort
Shadi Gholizadeh¹, Sarah D. Mills², Rina S. Fox², Lisa Jewett^3,4, Linda Kwakkenbos^3,4, Marie-Eve Carrier⁵, Brett D. Thombs^3,5, Scott C. Roesch^2,6, Vanessa L. Malcarne^2,6, Karen Gottesman⁷ and SPIN Investigators, ¹Psychoogy, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ³McGill University, Montreal, QC, Canada, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ⁶Psychology, San Diego State University, San Diego, CA, ⁷Scleroderma Foundation, Los Angeles, CA
Background/Purpose: The experience of living with a serious illness, such as systemic sclerosis (SSc), can pose challenges for an individual’s self-concept and social roles. This…
Abstract Number: 2145 • 2015 ACR/ARHP Annual Meeting
Ixekizumab Improves Physical Function, Quality of Life, and Work Productivity in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
Alice B. Gottlieb¹, Philip J. Mease², Raquel S. Cuchacovich^3,4, Catherine L. Shuler⁵, Chen-Yen Lin⁵, Russel T. Burge⁵, Suvajit Samanta⁵, Chin H. Lee⁵ and Dafna D. Gladman⁶, ¹Dermatology, Tufts Medical Center, Boston, MA, ²Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA, ³School of Medicine, Rheumatology Division, Indiana University, Indianapolis, IN, ⁴Bio Medicines Business Unit/Autoimmune Medical, Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease associated with psoriasis, peripheral arthritis, enthesitis, dactylitis, and spondylitis. PsA has a significant negative impact…
Abstract Number: 2323 • 2015 ACR/ARHP Annual Meeting
Patient Priorities in Rheumatoid Arthritis (RA) Research: An Exploration of Patient Perspectives from Those Enrolled in an Ontario RA Cohort
Laura Fullerton¹, Angela Cesta², Catherine Hoffstetter³ and Claire Bombardier^2,4,5, ¹Support, Systems and Outcomes, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³Patient partner, Toronto, ON, Canada, ⁴Division of Rheumatology and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Patient experiences with rheumatoid arthritis (RA) symptoms, treatments, and rheumatology care are critically important for the assessment of treatment-effectiveness and quality of care for…
Abstract Number: 2608 • 2015 ACR/ARHP Annual Meeting
The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission
Ricardo J.O. Ferreira^1,2, Cátia Duarte^1,3, Sylvie Batista³, Catarina Medeiros³, J.P. Sousa³, Gisela Eugénio¹, Carlos Costa¹, Pedro Carvalho¹, Joana F. Ferreira¹, Margarida Coutinho^1,4, Maria J. Salvador^1,4, Laure Gossec⁵ and J.A.P. da Silva^3,6, ¹Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal, ²Health Sciences Research Unit: Nursing (UICISA: E), Coimbra, Portugal, ³Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁴Clínica Universitária de Reumatologia, Faculty of Medicine, Universidade de Coimbra, Coimbra, Portugal, ⁵Rheumatology, Pitié Salpetriere Hospital, Paris, France, ⁶Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal
Background/Purpose: The "Rheumatoid Arthritis Impact of Disease" (RAID) score is a Patient Reported Outcome (PRO) that comprises seven domains of disease[1], that may reflect the…
Abstract Number: 2615 • 2015 ACR/ARHP Annual Meeting
Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity
Elizabeth R. Wahl^1,2, Andrew Gross², Vladimir Chernitskiy², Patricia P. Katz² and Jinoos Yazdany³, ¹Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA
Background/Purpose: A brief patient-reported measure of physical function, the PROMIS PF-10a, is sensitive to changes in disease activity among patients with rheumatoid arthritis (RA). However,…
Abstract Number: 2488 • 2014 ACR/ARHP Annual Meeting
Relationship Between Different Clinical Measurements and Patient-Reported Outcomes
Roy Fleischmann¹, V Strand², B Wilkinson³, K Kwok⁴ and E Bananis³, ¹Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Department of Medicine, Dallas, TX, ²Biopharmaceutical Consultant, Portola Valley, CA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we compare the relationship between clinical measures and patient-reported…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 420 • 2014 ACR/ARHP Annual Meeting
Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population
Elizabeth R. Wahl¹, Andrew J. Gross², R Krishna Chaganti¹, Lianne S. Gensler³, Vladimir Chernitskiy¹, Laura Trupin², Patricia P. Katz² and Jinoos Yazdany², ¹Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Patient-reported outcome measures are important tools that assess the impact of disease on patients' lives; in RA, patient-reported physical function is especially relevant. In…
Abstract Number: 2334 • 2013 ACR/ARHP Annual Meeting
ORAL SCAN: Effects Of The Oral JAK Inhibitor Tofacitinib In Combination With Methotrexate On Patient Reported Outcomes In a 24-Month Phase 3 Trial Of Active Rheumatoid Arthritis
V. Strand¹, D. van der Heijde², C. a. F. Zerbini³, C. A. Connell⁴, D. Gruben⁴, R. Riese⁴ and G. Wallenstein⁴, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Efficacy, inhibition of structural damage, and safety of tofacitinib…
Abstract Number: 2346 • 2013 ACR/ARHP Annual Meeting
Effects Of Tofacitinib, An Oral Janus Kinase Inhibitor, On Work Limitations In Patients With Rheumatoid Arthritis
Vibeke Strand¹, Keith S. Kanik², Carol Connell², Bethanie Wilkinson², David Gruben² and Gene Wallenstein², ¹Stanford University, Palo Alto, CA, ²Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Participation, in particular work productivity, is increasingly recognized as…
Abstract Number: 2350 • 2013 ACR/ARHP Annual Meeting
Effects Of VX-509, An Investigational Oral Selective Janus Kinase 3 (JAK3) Inhibitor, On Patient-Reported Outcomes In a Phase 2A Study Of Patients With Active Rheumatoid Arthritis
Vibeke Strand¹, Ellison Suthoff², Roy Fleischmann³, Montserrat Vera-Llonch⁴, John Jiang², Yanqiong Zhang² and Nils Kinnman⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Vertex Pharmaceuticals Incorporated, Cambridge, MA, ³Metroplex Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Vertex Pharamceuticals Incorporated, Cambridge, MA, ⁵Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral JAK3 inhibitor being evaluated as a treatment for RA. Safety and efficacy results from a phase 2a, 12-week, randomized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].